Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen and Metformin for Prevention of Oral Cancer in Fanconi Anemia
NCT07901959Phase 1Recruiting
- Sponsor
- The Rockefeller University
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) and Aprol in head and neck cancer (HNC) and squamous cell carcinoma (SCC) (3 arms), sponsored by The Rockefeller University. Primary endpoints: Safety at 22 months and Tolerability of Intervention Regimen. Started Oct 2026; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)Aprol
03
Conditions
head and neck cancer (HNC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT07901959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901959.